REVIEW PAPER
Comprehensive review on herbal remedies treatment for acquired immune deficiency syndrome (AIDS)
1
Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, India
These authors had equal contribution to this work
Submission date: 2023-06-30
Final revision date: 2023-10-04
Acceptance date: 2024-05-03
Online publication date: 2025-07-15
Corresponding author
Sushma Verma
Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida -201306
Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida -201306
HIV & AIDS Review 2025;24(3):175-183
KEYWORDS
human immunodeficiency virusbaicaleinHypoxisHemerocallisSutherlandia frutescensEuphorbiaceaeacquired immune deficiency syndrome
TOPICS
ABSTRACT
This thorough review aimed to present critical examination of the literature on the subject, and assess the effectiveness of herbal medicines for the treatment of acquired immune deficiency syndrome (AIDS). This evaluation presented how herbal medications are used in conventional and alternative medical systems, investigated scientific data supporting their usefulness, and showed difficulties and potential benefits of incorporating herbal medicines into human immunodeficiency virus/AIDS treatment plans.
The analysis discovered that several herbal treatments were studied for their ability to cure AIDS, mostly as a complementary therapy to traditional antiretroviral medication. Studies demonstrated the immunomodulatory qualities of several herbs, including Scutellaria baicalensis, Hypoxis hemerocallidea, and Sutherlandia frutescens, which may help AIDS patients’ immune systems function better.
Herbal medicines have a beneficial potential as adjunctive treatments for individuals with AIDS, mainly by strengthening immune function and improving general health. Patients should not, however, rely exclusively on herbal remedies, and their usage must be monitored by medical specialists. More investigations are needed to determine particular herbal ingredients and combinations, which may significantly improve the management of AIDS, taking into account possible drug interactions with antiretrovirals.
REFERENCES (62)
1.
Besednova NN, Zvyagintseva TN, Kuznetsova TA, Makarenkova ID, Smolina TP, Fedyanina LN, et al. Marine algae metabolites as promising therapeutics for the prevention and treatment of HIV/AIDS. Metabolites 2019; 9: 87. DOI: 10.3390/metabo9050087.
2.
Jin H, Chong H, Zhu Y, Zhang M, Li X, Bazybek N, et al. Preparation and evaluation of amphipathic lipopeptide-loaded PLGA microspheres as a sustained-release system for AIDS prevention. Eng Life Sci 2020; 20: 476-484.
3.
Jenita JL, Chocalingam V, Wilson B. Albumin nanoparticles coated with polysorbate 80 as a novel drug carrier for the delivery of antiretroviral drug-efavirenz. Int J Pharm Investig 2014; 4: 142-148.
4.
Nyamukuru A, Tabuti JRS, Lamorde M, Kato B, Sekagya Y, Aduma PR. Medicinal plants and traditional treatment practices used in the management of HIV/AIDS clients in Mpigi District, Uganda. J Herb Med 2017; 7: 51-58.
5.
Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D’Souza G, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med 2015; 163: 507-518.
6.
Uckun FM, Qazi S, Venkatachalam TK. In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforschung 2005; 55: 223-231.
7.
Flexner C, Thomas DL, Swindells S. Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis. Curr Opin HIV AIDS 2019; 14: 13-20.
8.
Cattaneo D, Andreoni M, Carosi G, Cauda R, Lazzarin A, Rizzardini G. Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries? Int J Clin Pharmacol Ther 2017; 55: 381-393.
9.
Napper LE, Fisher DG, Reynolds GL, Johnson ME. HIV risk behavior self-report reliability at different recall periods. AIDS Behav 2010; 14: 152-161.
11.
Özsoy M, Ernst E. How effective are complementary therapies for HIV and AIDS? – a systematic review. Int J STD AIDS 1999; 10: 629-635.
12.
Faragon JJ, Purdy BD, Piliero PJ. An assessment of herbal therapy use, adherence, and utilization of pharmacy services in HIV clinics. J Herb Pharmacother 2002; 2: 27-37.
13.
Qian Z, Zhang Y, Xie X, Wang J. Efficacy and safety of traditional Chinese herbal medicine combined with HAART in the treatment of HIV/AIDS: a protocol for systematic review and meta-analysis. Medicine 2021; 100: e28287. DOI: 10.1097/MD.0000000000028287.
14.
Lu DY, Wu HY, Lu TR. HIV/AIDS treatment, therapeutic strategy breakthroughs. Hospice Palliat Med Int J 2020; 4: 34-39.
15.
Da-Yong L, Ting-Ren L. Herbal medicine in new era. Hospice Palliat Med Int J 2019; 3: 125-130.
16.
Lu D, Lu TR. Drug discoveries from natural resources. J Prim Health Care Gen Pract 2019; 8: 8-11.
17.
Wu HF, Morris‐Natschke SL, Xu XD, Yang MH, Cheng YY, Yu SS, et al. Recent advances in natural anti‐HIV triterpenoids and analogs. Med Res Rev 2020; 40: 2339-2385.
18.
Habibi P, Daniell H, Soccol CR, Grossi‐de‐Sa MF. The potential of plant systems to break the HIV‐TB link. Plant Biotechnol J 2019; 17: 1868-1891.
19.
Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S, Flanagan KL, Macallan DC. Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. Rev Med Virol 2013; 23: 221-240.
20.
Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 2011; 1: a006841. DOI: 10.1101/cshperspect.a006841.
21.
Esbjörnsson J, Månsson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med 2012; 367: 224-232.
22.
Peterson K, Ruelle J, Vekemans M, Siegal FP, Deayton JR, Colebunders R. The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series. Antivir Ther 2012; 17: 1097-1100.
23.
Peterson K, Jallow S, Rowland-Jones SL, de Silva TI. Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. AIDS Res Treat 2011; 2011: 463704. DOI: 10.1155/2011/463704.
24.
Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011; 52: 780-787.
26.
Harrison SC. Mechanism of membrane fusion by viral envelope proteins. Adv Virus Res 2005; 64: 231-261.
27.
Yang SS, Cragg GM, Newman DJ, Bader JP. Natural product-based anti-HIV drug discovery and development facilitated by the NCI Developmental Therapeutics Program. J Nat Prod 2001; 64: 265-277.
28.
Huang KC. Tonics and supporting herbs. In: The Pharmacology of Chinese Herbs. Boca Raton: CRC Press; 1999, pp. 263-264.
29.
Wu JA, Attele AS, Zhang L, Yuan CS. Anti-HIV activity of medicinal herbs: usage and potential development. Am J Chin Med 2001; 29: 69-81.
30.
Baylor NW, Fu T, Yan YD, Ruscetti FW. Inhibition of human T cell leukemia virus by the plant flavonoid baicalin (7-glucuronic acid, 5,6-dihydroxyflavone). J Infect Dis 1992; 165: 433-437.
31.
Ng TB, Huang B, Fong WP, Yeung HW. Anti-human immunodeficiency virus (anti-HIV) natural products with special emphasis on HIV reverse transcriptase inhibitors. Life Sci 1997; 61: 933-949.
32.
Zhao J, Zhang Z, Chen H, Zhang X, Chen X. Synthesis of baicalin derivatives and evaluation of their anti-human immunodeficiency virus (HIV-1) activity. Yao Xue Xue Bao 1998; 33: 22-27.
33.
Piscaglia M, Cossu MV, Passerini M, Petri F, Gerbi M, Fusetti C, et al. Emerging drugs for the treatment of HIV/AIDS: a review of 2019/2020 phase II and III trials. Expert Opin Emerg Drugs 2021; 26: 219-230.
34.
Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med 2019; 381: 803-815.
35.
Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med 2017; 18: 56-63.
36.
Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl) 2015; 7: 95-104.
37.
Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, et al. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 2010; 24: 395-403.
38.
Tsiodras S, Perelas A, Wanke C, Mantzoros CS. The HIV-1/HAART associated metabolic syndrome – novel adipokines, molecular associations and therapeutic implications. J Infect 2010; 61: 101-113.
39.
Brinkworth RI, Stoermer MJ, Fairlie DP. Flavones are inhibitors of HIV-1 proteinase. Biochem Biophys Res Commun 1992; 188: 631-637.
40.
Kitamura K, Honda M, Yoshizaki H, Yamamoto S, Nakane H, Fukushima M, et al. Baicalin, an inhibitor of HIV-1 production in vitro. Antiviral Res 1998; 37: 131-140.
41.
Ono K, Nakane H. Mechanisms of inhibition of various cellular DNA and RNA polymerases by several flavonoids. J Biochem 1990; 108: 609-613.
42.
Gao Z, Huang K, Yang X, Xu H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta 1999; 1472: 643-650.
43.
Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, et al. Effects of Sho‐saiko‐to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29: 149-160.
44.
Yagura M, Murai S, Kojima H, Tokita H, Kamitsukasa H, Harada H. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-α therapy: including quantitative assessment by a morphometric method. J Gastroenterol 2000; 35: 105-111.
45.
Mills E, Cooper C, Seely D, Kanfer I. African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr J 2005; 4: 19. DOI: 10.1186/1475-2891-4-19.
46.
Singh Y. Hypoxis yellow stars of horticulture, folk remedies and conventional medicine. Veld Flora 1999; 85: 123-125.
47.
Wilt TJ, Ishani A, Rutks I, MacDonald R. Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 2000; 3(4A): 459-472.
48.
Mahomed IM, Ojewole JA. Hypoglycemic effect of Hypoxis hemerocallidea corm (African potato) aqueous extract in rats. Methods Find Exp Clin Pharmacol 2003; 25: 617-623.
49.
Bouic PJ, Clark A, Brittle W, Lamprecht JH, Freestone M, Liebenberg RW. Plant sterol/sterolin supplement use in a cohort of South African HIV-infected patients: effects on immunological and virological surrogate markers. S Afr Med J 2001; 91: 848-850.
50.
Whitney JR, Billoski TV, Jones VR. Evidence for triceratops in Antarctica. In: New Directions in Paleontology. Billoski TV (ed.). Academic Press; 1997, pp. 24-27.
51.
Gericke N. Clinical application of selected South African medicinal plants. Aust J Med Herbalism 2001; 13: 3-7, 9-11, 13-15.
52.
Dalvi S. Sutherlandia as Support for immune dysfunction. Posit Health 2003; 85: 23-25.
53.
Glastonbury S. Propagating and growing Sutherlandia frutescens in Australia: an overlooked opportunity? Aust J Herb Med 2013; 25: 18-19, 40.
54.
Fernandes AC, Cromarty AD, Albrecht C, van Rensburg CE. The antioxidant potential of Sutherlandia frutescens. J Ethnopharmacol 2004; 95: 1-5.
55.
Tai J, Cheung S, Chan E, Hasman D. In vitro culture studies of Sutherlandia frutescens on human tumor cell lines. J Ethnopharmacol 2004; 93: 9-19.
56.
Uchiumi F, Hatano T, Ito H, Yoshida T, Tanuma SI. Transcriptional suppression of the HIV promoter by natural compounds. Antiviral Res 2003; 58: 89-98.
57.
Notka F, Meier G, Wagner R. Concerted inhibitory activities of Phyllanthus amarus on HIV replication in vitro and ex vivo. Antiviral Res 2004; 64: 93-102.
58.
Naik AD, Juvekar AR. Effects of alkaloidal extract of Phyllanthus niruri on HIV replication. Indian J Med Sci 2003; 57: 387-393.
59.
Abd-Elazem IS, Chen HS, Bates RB, Huang RC. Isolation of two highly potent and non-toxic inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase from Salvia miltiorrhiza. Antiviral Res 2002; 55: 91-106.
60.
Xu ZQ, Barrow WW, Suling WJ, Westbrook L, Barrow E, Lin YM, et al. Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis. Bioorg Med Chem 2004; 12: 1199-1207.
61.
Chinkwo KA. Sutherlandia frutescens extracts can induce apoptosis in cultured carcinoma cells. J Ethnopharmacol 2005; 98: 163-170.
62.
Harnett SM, Oosthuizen VD, Van de Venter M. Anti-HIV activities of organic and aqueous extracts of Sutherlandia frutescens and Lobostemon trigonus. J Ethnopharmacol 2005; 96: 113-119.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
